Cargando…

Comparison of metabolic pathways of different α-N-heterocyclic thiosemicarbazones

Clinical failure of novel drugs is often related to their rapid metabolism and excretion. This highlights the importance of elucidation of their pharmacokinetic profile already at the preclinical stage of drug development. Triapine, the most prominent representative of α-N-heterocyclic thiosemicarba...

Descripción completa

Detalles Bibliográficos
Autores principales: Pelivan, Karla, Frensemeier, Lisa M., Karst, Uwe, Koellensperger, Gunda, Heffeter, Petra, Keppler, Bernhard K., Kowol, Christian R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5849672/
https://www.ncbi.nlm.nih.gov/pubmed/29476231
http://dx.doi.org/10.1007/s00216-018-0889-x
_version_ 1783306077964599296
author Pelivan, Karla
Frensemeier, Lisa M.
Karst, Uwe
Koellensperger, Gunda
Heffeter, Petra
Keppler, Bernhard K.
Kowol, Christian R.
author_facet Pelivan, Karla
Frensemeier, Lisa M.
Karst, Uwe
Koellensperger, Gunda
Heffeter, Petra
Keppler, Bernhard K.
Kowol, Christian R.
author_sort Pelivan, Karla
collection PubMed
description Clinical failure of novel drugs is often related to their rapid metabolism and excretion. This highlights the importance of elucidation of their pharmacokinetic profile already at the preclinical stage of drug development. Triapine, the most prominent representative of α-N-heterocyclic thiosemicarbazones, was investigated in more than 30 clinical phase I/II trials, but the results against solid tumors were disappointing. Recent investigations from our group suggested that this is, at least partially, based on the fast metabolism and excretion. In order to establish more detailed structure/activity/metabolism relationships, herein a panel of 10 different Triapine derivatives was investigated for their metabolic pathways. From the biological point of view, the panel consists of terminally dimethylated thiosemicarbazones with nanomolar IC(50) values, derivatives with micromolar cytotoxicities comparable to Triapine and a completely inactive representative. To study the oxidative metabolism, a purely instrumental approach based on electrochemistry/mass spectrometry was applied and the results were compared to the data obtained from microsomal incubations. Overall, the investigated thiosemicarbazones underwent the phase I metabolic reactions dehydrogenation, hydroxylation, oxidative desulfuration (to semicarbazone and amidrazone) and demethylation. Notably, dehydrogenation resulted in a ring-closure reaction with formation of thiadiazoles. Although strong differences between the metabolic pathways of the different thiosemicarbazones were observed, they could not be directly correlated to their cytotoxicities. Finally, the metabolic pathways for the most cytotoxic compound were elucidated also in tissues collected from drug-treated mice, confirming the data obtained by electrochemical oxidation and microsomes. In addition, the in vivo experiments revealed a very fast metabolism and excretion of the compound. [Figure: see text] ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00216-018-0889-x) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5849672
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-58496722018-03-21 Comparison of metabolic pathways of different α-N-heterocyclic thiosemicarbazones Pelivan, Karla Frensemeier, Lisa M. Karst, Uwe Koellensperger, Gunda Heffeter, Petra Keppler, Bernhard K. Kowol, Christian R. Anal Bioanal Chem Research Paper Clinical failure of novel drugs is often related to their rapid metabolism and excretion. This highlights the importance of elucidation of their pharmacokinetic profile already at the preclinical stage of drug development. Triapine, the most prominent representative of α-N-heterocyclic thiosemicarbazones, was investigated in more than 30 clinical phase I/II trials, but the results against solid tumors were disappointing. Recent investigations from our group suggested that this is, at least partially, based on the fast metabolism and excretion. In order to establish more detailed structure/activity/metabolism relationships, herein a panel of 10 different Triapine derivatives was investigated for their metabolic pathways. From the biological point of view, the panel consists of terminally dimethylated thiosemicarbazones with nanomolar IC(50) values, derivatives with micromolar cytotoxicities comparable to Triapine and a completely inactive representative. To study the oxidative metabolism, a purely instrumental approach based on electrochemistry/mass spectrometry was applied and the results were compared to the data obtained from microsomal incubations. Overall, the investigated thiosemicarbazones underwent the phase I metabolic reactions dehydrogenation, hydroxylation, oxidative desulfuration (to semicarbazone and amidrazone) and demethylation. Notably, dehydrogenation resulted in a ring-closure reaction with formation of thiadiazoles. Although strong differences between the metabolic pathways of the different thiosemicarbazones were observed, they could not be directly correlated to their cytotoxicities. Finally, the metabolic pathways for the most cytotoxic compound were elucidated also in tissues collected from drug-treated mice, confirming the data obtained by electrochemical oxidation and microsomes. In addition, the in vivo experiments revealed a very fast metabolism and excretion of the compound. [Figure: see text] ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00216-018-0889-x) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2018-02-23 2018 /pmc/articles/PMC5849672/ /pubmed/29476231 http://dx.doi.org/10.1007/s00216-018-0889-x Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Research Paper
Pelivan, Karla
Frensemeier, Lisa M.
Karst, Uwe
Koellensperger, Gunda
Heffeter, Petra
Keppler, Bernhard K.
Kowol, Christian R.
Comparison of metabolic pathways of different α-N-heterocyclic thiosemicarbazones
title Comparison of metabolic pathways of different α-N-heterocyclic thiosemicarbazones
title_full Comparison of metabolic pathways of different α-N-heterocyclic thiosemicarbazones
title_fullStr Comparison of metabolic pathways of different α-N-heterocyclic thiosemicarbazones
title_full_unstemmed Comparison of metabolic pathways of different α-N-heterocyclic thiosemicarbazones
title_short Comparison of metabolic pathways of different α-N-heterocyclic thiosemicarbazones
title_sort comparison of metabolic pathways of different α-n-heterocyclic thiosemicarbazones
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5849672/
https://www.ncbi.nlm.nih.gov/pubmed/29476231
http://dx.doi.org/10.1007/s00216-018-0889-x
work_keys_str_mv AT pelivankarla comparisonofmetabolicpathwaysofdifferentanheterocyclicthiosemicarbazones
AT frensemeierlisam comparisonofmetabolicpathwaysofdifferentanheterocyclicthiosemicarbazones
AT karstuwe comparisonofmetabolicpathwaysofdifferentanheterocyclicthiosemicarbazones
AT koellenspergergunda comparisonofmetabolicpathwaysofdifferentanheterocyclicthiosemicarbazones
AT heffeterpetra comparisonofmetabolicpathwaysofdifferentanheterocyclicthiosemicarbazones
AT kepplerbernhardk comparisonofmetabolicpathwaysofdifferentanheterocyclicthiosemicarbazones
AT kowolchristianr comparisonofmetabolicpathwaysofdifferentanheterocyclicthiosemicarbazones